Minneapolis Hematology and Breast Cancer Conference

Minneapolis, MN US
February 23, 2024 to February 24, 2024

The Minneapolis Hematology and Breast Cancer Conference, is a CME-accredited, in-person hematology oncology conference featuring leading hematology and breast cancer experts. Expert faculty will place key abstract findings from the 65th ASH Annual Meeting (ASH2023) and the San Antonio Breast Cancer Symposium (SABCS2023) into clinical context and discuss how the results may change the current standards of care for patients with benign and malignant hematologic disorders and breast cancer. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.

This conference allows attendees an opportunity to discuss current research and advances in the field of hematologic disorders and breast cancer with colleagues and key opinion leaders. The goals of this conference are to review and critically assess the results of practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients. 

Target Audience

  • Hematologists, Oncologists
  • Surgeons
  • Radiation Oncologists
  • Physician Assistants/Nurse Practitioners
  • Pharmacists
  • Nurses

ORGANIZING COMMITTEE 

Course Director:

Binay Shah, MD, MHA Binaytara Foundation

Conference Chair:

Shaji Kumar, MD - Mayo Clinic

Roberto Leon Ferre, MD - Mayo Clinic

VENUE INFORMATION 

Booking link: 

If you are attending this meeting and need to reserve a hotel room, please reserve your room at the link below to take advantage of the discounted group rate of $109 per night plus applicable taxes and fees. The cut off date is January 31, 2024:

https://www.sonesta.com/royal-sonesta/mn/minneapolis/royal-sonesta-minneapolis-downt[…]&groupCode=G022224BINA&checkin=2024-02-22&checkout=2024-02-25

Learning Objectives

  1. Review data presented at the ASH2023 and SABCS2023 & discuss their applications in clinical settings.    
  2. Choose new therapeutic options for treating benign and malignant hematologic disorders & breast cancer, understanding appropriate indications and contraindications to these therapeutic approaches.
  3. Discuss the study design and primary endpoints of recently reported and ongoing trials that have influenced the changes in the standards of care in hematology and breast cancer.
  4. Integrate evolving diagnostic, prognostic, and therapeutic approaches to managing hematologic disorders and breast cancer patients.
  5. Individualize management of patients based on emerging data from clinical trials and evolving expert guidelines.

 

GLOBAL ONCOLOGY PROJECT

Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/

Course summary
Available credit: 
  • 8.25 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.25 Contact Hours.
Course opens: 
11/16/2023
Course expires: 
05/17/2024
Event starts: 
02/23/2024 - 4:00pm PST
Event ends: 
02/24/2024 - 4:30pm PST
Cost:
$200.00

DAY 1 - February 23rd, 2024

All times are listed in Central Time (CT)

04:00 PM – 04:45 PM: Registration/Networking & Exhibits


04:45 PM – 05:00 PM: Opening remarks


05:00 PM – 06:45 PM: Session 1

Session Chair: Shaji Kumar, MD

05:00 PM – 05:25 PM: Lymphoma - Patrick Johnston, MD, PhD

05:25 PM – 05:50 PM: Chronic lymphocytic leukemia - Paul Hampel, MD

05:50 PM – 06:15 PM: Multiple myeloma - Joselle Cook, MD

06:15 PM – 06:45 PM: Q & A


06:45 PM – 07:30 PM: Networking/reception & Exhibits


DAY 2 - February 24th, 2024

07:00 AM – 07:55 AM: Breakfast & Exhibits


08:00 AM – 09:30 AM: Session 2

Session Chair: Guru Subramanian Guru Murthy, MD, MS

08:00 AM – 08:25 AM: MDS/Acute Leukemia - Aref Al-Kali, MD

08:25 AM – 08:50 AM: Myeloproliferative neoplasms and CML - Jeremy Allred, MD

08:50 AM – 09:15 AM: Cellular therapy in hematologic malignancies – recent updates - Mithun Shah, MD, PhD

09:15 AM – 09:30 AM: Q & A


09:30 AM – 10:00 AM:  Break & exhibits


10:00 AM – 11:30 AM: Session 3 – Case-based discussion

Session Chair: George Rodgers, MD, PhD

Case 1 – Bleeding disorder - Doris Quon, MD, PhD

Case 2 – Clotting disorder - George Rodgers, MD, PhD

Case 3 – ITP/TTP - Meera Sridharan, MD, PhD

Case 4 – Anemia - Meera Sridharan, MD, PhD

Case 5 – Bone marrow failure - Aditi Sharma, MD


11:30 AM - 12:30 PM: Lunch & exhibits


12:30 PM - 02:15 PM: Session 4

Session Chair: Priya Kumar, MD

12:30 PM - 12:55 PM: Hormone receptor-positive breast cancer - Grace Choong, MD

12:55 PM - 01:20 PM: HER2-positive breast cancer - Stuart Bloom, MD, MSc

01:20 PM - 01:45 PM: Triple-negative and HER2 low breast cancer - Roberto Leon-Ferre, MD

01:45 PM – 02:15 PM: Q & A


02:15 PM – 02:30 PM: Break & exhibits


02:30 PM – 04:15 PM: Session 5

Session Chair: Roberto Leon-Ferre, MD 

02:30 PM – 02:55 PM: Radiotherapy – best breast practice - Kimberly Corbin, MD

02:55 PM – 03:20 PM: Updates in surgical approach – best breast practice - Jeffrey Johnson, MD

03:20 PM – 03:45 PM: Q & A

03:45 PM – 04:15 PM: Case-based discussion

Case 1 - Ashley Hickman, MD

Case 2 – Considerations in early breast cancer - Applications of recent data - Sarah Premji, MD

Case 3 – Early stage breast cancer - Dhauna Karam, MBBS, MD, FACP


04:15 PM – 04:20 PM: Adjourn

The Royal Sonesta Minneapolis Downtown
35 S 7th St
Minneapolis, MN 55402
United States

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Conference Chair(s)

Shaji Kumar, MD

has a financial relationship (Professional Services) with Consulting/Advisory Board participation: (with no personal payments) Abbvie, Amgen, BMS, Janssen,  Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secure Biotherapeutics and (with personal payment) Oncopeptides, Beigene, Antengene ;.
has a financial relationship (Grant Or Contract) with Research funding for clinical trials to the institution: Abbvie, Amgen, BMS, Carsgen,  Janssen,  ,  Astra-Zeneca, Novartis, Roche-Genentech,  Takeda, Tenebio, Molecular Templates;.

Roberto Leon-Ferre

has a financial relationship (Other) with Gilead;.
has a financial relationship (Other) with Lyell;.
has a financial relationship (Other) with AstraZeneca;.
Session Chair(s)

Guru Subramanian Guru Murthy, MD, MS

has a financial relationship (Other) with Pfizer;.
has a financial relationship (Other) with Autolus;.
has a financial relationship (Other) with Gilead;.
has a financial relationship (Other) with Kite;.
has a financial relationship (Other) with Amgen;.
has a financial relationship (Other) with BMS;.
has a financial relationship (Other) with Rigel;.
has a financial relationship (Other) with BeiGene;.
has a financial relationship (Other) with Amgen;.

Priya Kumar

has no relevant financial relationships to disclose at this time.

Siddhartha Yadav, Siddhartha Yadav, MD, FACP

has a financial relationship (Other) with Repare Therapeutics;.
has a financial relationship (Other) with Astrazenca ;.
has a financial relationship (Other) with Astrazeneca ;.
Speaker/Topic Presenter(s)

Aref Al-Kali, MD

has a financial relationship (Grant Or Contract) with ASTX;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with H3b Biomedicine;.
has a financial relationship (Grant Or Contract) with ALX Oncology;.

Jeremy Allred, MD

has no relevant financial relationships to disclose at this time.

Anne Blaes, MD MS

has no relevant financial relationships to disclose at this time.

Stuart Bloom

has no relevant financial relationships to disclose at this time.

Grace Choong

has no relevant financial relationships to disclose at this time.

Joselle Cook

has no relevant financial relationships to disclose at this time.

Kimberly Corbin

has no relevant financial relationships to disclose at this time.

Paul Hampel, M.D.

has no relevant financial relationships to disclose at this time.

Jeffrey Johnson

has a financial relationship (Employment) with CG Oncology;.

Patrick Johnston, MD/PhD

has no relevant financial relationships to disclose at this time.

Roberto Leon-Ferre

has a financial relationship (Other) with AstraZeneca;.
has a financial relationship (Other) with Gilead;.
has a financial relationship (Other) with Lyell;.

Mithun Shah, MD, PhD

has a financial relationship (Grant Or Contract) with MRKR Therapeutics;.
has a financial relationship (Grant Or Contract) with AbbVie;.
has a financial relationship (Grant Or Contract) with Astellas;.
has a financial relationship (Grant Or Contract) with KURA Oncology;.
has a financial relationship (Grant Or Contract) with Celgene;.

Meera Sridharan, MD, PhD; Assistant Professor of medicine and oncology , consultant Division of Hematology, Department of Internal Medicine Rochester, MN

has a financial relationship (Professional Services) with Excel Co;.
has a financial relationship (Professional Services) with Sanofi Genzyme;.
Case Presenter(s)

Ashley Hickman, MD

has no relevant financial relationships to disclose at this time.

Dhauna Karam, MBBS, MD, FACP

has no relevant financial relationships to disclose at this time.

Sarah Premji, MD

has no relevant financial relationships to disclose at this time.

Doris Quon, MD, PhD

has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with CSL Behring;.
has a financial relationship (Professional Services) with Biomarin;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with Roche/Genentech;.
has a financial relationship (Professional Services) with NovoNordisk;.
has a financial relationship (Professional Services) with Takeda;.

GEORGE RODGERS, MD, PhD

has a financial relationship (Professional Services) with American Regent;.
has a financial relationship (Professional Services) with Alexion;.
has a financial relationship (Professional Services) with Novartis;.

Aditi Sharma, MD

has no relevant financial relationships to disclose at this time.

Available Credit

  • 8.25 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.25 Contact Hours.

We would like to thank the following exhibitors and sponsors for supporting this meeting.

NameSponsorship TypeRep Name
AstraZeneca Platinum SponsorStephanie Munyon
AstraZeneca 2nd tableGeneral ExhibitStephanie Munyon
BiotheranosticsGeneral ExhibitHeidi Keller
Bristol Myers SquibbGeneral ExhibitJohn Hughes
Daiichi Sankyo, Inc.General ExhibitStephanie Ohlmann
ExelixisGeneral ExhibitAmy Modean
Gilead Sciences, Inc.General ExhibitRob Kim
IncyteGeneral ExhibitJenny Dahlke
IpsenGeneral ExhibitMaria Lewis
Karyopharm TherapeuticsGeneral ExhibitStephanie Kimel
Lilly OncologyGeneral ExhibitJennea Botts
Menarini StemlineGeneral ExhibitMatt Krusemark
Pfizer Breast TeamGeneral ExhibitTony Doherty
Pfizer Hematology TeamGeneral ExhibitDaniel Morgan
SanofiGeneral ExhibitKevin Methe
ServierGeneral ExhibitKim Tremain

 

Price

Cost:
$200.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

If your company has purchased an exhibit or sponsorship, please register at the link below to receive the discounted registration fees:

Link to register as an additional rep of a sponsoring company: https://education.binayfoundation.org/industry_registraiton_nocme 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.